Graft Options in Posterolateral and Posterior Interbody Lumbar Fusion

Study Design. Review article, review of literature. Objective. To review the bone graft options that exist for posterolateral and posterior interbody lumbar fusion. Summary of Background Data. As the number of lumbar fusion surgeries has increased over the last decade, alternative methods of grafting have been developed. Iliac crest autograft bone has traditionally been used for lumbar fusion. The downside to this graft option, however, is donor site morbidity. Methods. The current literature on alternatives to iliac crest autograft bone for obtaining lumbar fusion was reviewed. Results. Platelet gels, demineralized bone matrix, synthetic bone graft, and bone morphogenetic protein are potential options for bone graft supplementation or substitution. In preclinical studies, platelet gels have been beneficial to bone growth when combined with autograft, but clinical studies do not support the use of platelet gel in posterolateral lumbar fusion. Preclinical studies of demineralized bone matrix have shown significant variability in the osteoinductive properties of the available products, and clinical data showing efficacy is limited. The use of synthetic bone graft material (ceramics) in lumbar fusion surgery is increasing. Calcium phosphate compounds (i.e., &bgr;-tricalcium phosphate and hydroxyapetite) are most commonly used and are often combined with type I collagen to form a matrix. These materials provide an osteoconductive scaffold for bony ingrowth and can be combined with bone marrow aspirate or used as a carrier for osteogenic factors. Bone morphogenetic protein (rhBMP-2) has been shown to provide similar or even increased fusion rates over autograft iliac crest bone. There are, however, potential safety concerns associated with the use of bone morphogenetic protein that are not fully understood. Conclusion. Several alternatives to iliac crest autograft bone provide promising early clinical results in achieving posterolateral and posterior interbody lumbar fusion.

[1]  S. Glassman,et al.  Two-year fusion and clinical outcomes in 224 patients treated with a single-level instrumented posterolateral fusion with iliac crest bone graft. , 2009, The spine journal : official journal of the North American Spine Society.

[2]  T. Albert,et al.  Complications associated with single-level transforaminal lumbar interbody fusion. , 2009, The spine journal : official journal of the North American Spine Society.

[3]  S. Glassman,et al.  Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. , 2009, The Journal of bone and joint surgery. American volume.

[4]  M. Rahm,et al.  Clinical and radiographic assessment of transforaminal lumbar interbody fusion using HEALOS collagen-hydroxyapatite sponge with autologous bone marrow aspirate. , 2009, The spine journal : official journal of the North American Spine Society.

[5]  N. Epstein An analysis of noninstrumented posterolateral lumbar fusions performed in predominantly geriatric patients using lamina autograft and beta tricalcium phosphate. , 2008, The spine journal : official journal of the North American Spine Society.

[6]  L. Dai,et al.  Single-Level Instrumented Posterolateral Fusion of Lumbar Spine With &bgr;-Tricalcium Phosphate Versus Autograft: A Prospective, Randomized Study With 3-Year Follow-up , 2008, Spine.

[7]  T. Albert,et al.  The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. , 2008, The spine journal : official journal of the North American Spine Society.

[8]  S. Glassman,et al.  Adverse Events in Patients Re-Exposed to Bone Morphogenetic Protein for Spine Surgery , 2008, Spine.

[9]  M. Pećina,et al.  Re: Burkus J K, Sandhu H S, Gornet M F. Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft. Spine 2006;31:775-81. , 2008, Spine.

[10]  M. Pećina,et al.  Re: Burkus J K, Transfeldt E E, Kitchel S H, et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 2002;27:2396-408. , 2008, Spine.

[11]  T. Damron,et al.  Use of 3D β-tricalcium phosphate (Vitoss®) scaffolds in repairing bone defects , 2007 .

[12]  K. Lewandrowski,et al.  Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases. , 2007, The spine journal : official journal of the North American Spine Society.

[13]  W. Dhert,et al.  The Incidence of Donor Site Pain After Bone Graft Harvesting From the Posterior Iliac Crest May Be Overestimated: A Study on Spine Fracture Patients , 2007, Spine.

[14]  S. Boden,et al.  The Efficacy of rhBMP-2 for Posterolateral Lumbar Fusion in Smokers , 2007, Spine.

[15]  N. Haas,et al.  Quantification of various growth factors in different demineralized bone matrix preparations. , 2007, Journal of biomedical materials research. Part A.

[16]  Jay R. Lieberman,et al.  A comparison of commercially available demineralized bone matrix for spinal fusion , 2007, European Spine Journal.

[17]  James N Weinstein,et al.  United States’ Trends and Regional Variations in Lumbar Spine Surgery: 1992–2003 , 2006, Spine.

[18]  S. Glassman,et al.  Clinical Outcomes and Fusion Success at 2 Years of Single-Level Instrumented Posterolateral Fusions With Recombinant Human Bone Morphogenetic Protein-2/Compression Resistant Matrix Versus Iliac Crest Bone Graft , 2006, Spine.

[19]  Matthew Shaw,et al.  Healos and Bone Marrow Aspirate Used for Lumbar Spine Fusion: A Case Controlled Study Comparing Healos With Autograft , 2006, Spine.

[20]  N. Epstein A Preliminary Study of the Efficacy of Beta Tricalcium Phosphate as a Bone Expander for Instrumented Posterolateral Lumbar Fusions , 2006, Journal of spinal disorders & techniques.

[21]  S. Kitchel A preliminary comparative study of radiographic results using mineralized collagen and bone marrow aspirate versus autologous bone in the same patients undergoing posterior lumbar interbody fusion with instrumented posterolateral lumbar fusion. , 2006, The spine journal : official journal of the North American Spine Society.

[22]  R. Delamarter,et al.  Intervariability and Intravariability of Bone Morphogenetic Proteins in Commercially Available Demineralized Bone Matrix Products , 2006, Spine.

[23]  D. Sengupta,et al.  Outcome of Local Bone Versus Autogenous Iliac Crest Bone Graft in the Instrumented Posterolateral Fusion of the Lumbar Spine , 2006, Spine.

[24]  J. Burkus,et al.  Influence of rhBMP-2 on the Healing Patterns Associated With Allograft Interbody Constructs in Comparison With Autograft , 2006, Spine.

[25]  T. Albert,et al.  Comparison of OP-1 Putty (rhBMP-7) to Iliac Crest Autograft for Posterolateral Lumbar Arthrodesis: A Minimum 2-Year Follow-up Pilot Study , 2005, Spine.

[26]  K. Bulsara,et al.  Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. , 2005, Journal of neurosurgery. Spine.

[27]  John R. Johnson,et al.  Initial Fusion Rates With Recombinant Human Bone Morphogenetic Protein-2/Compression Resistant Matrix and a Hydroxyapatite and Tricalcium Phosphate/Collagen Carrier in Posterolateral Spinal Fusion , 2005, Spine.

[28]  B. Barnes,et al.  Lower Dose of rhBMP-2 Achieves Spine Fusion When Combined With an Osteoconductive Bulking Agent in Non-human Primates , 2005, Spine.

[29]  S. Glassman,et al.  Platelet Gel (AGF) Fails to Increase Fusion Rates in Instrumented Posterolateral Fusions , 2005, Spine.

[30]  W. Hutton,et al.  Comparison of Healos/Bone Marrow to INFUSE(rhBMP-2/ACS) With a Collagen-Ceramic Sponge Bulking Agent as Graft Substitutes for Lumbar Spine Fusion , 2005, Spine.

[31]  K. Shinomiya,et al.  Beta-tricalcium phosphate (beta-TCP) graft combined with bone marrow stromal cells (MSCs) for posterolateral spine fusion. , 2005, Journal of medical and dental sciences.

[32]  Kevin T Foley,et al.  Minimally Invasive Transforaminal Lumbar Interbody Fusion (TLIF): Technical Feasibility and Initial Results , 2005, Journal of spinal disorders & techniques.

[33]  T. Albert,et al.  A 2-year follow-up pilot study evaluating the safety and efficacy of op-1 putty (rhbmp-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions , 2005, European Spine Journal.

[34]  F. Castro Role of Activated Growth Factors in Lumbar Spinal Fusions , 2004, Journal of spinal disorders & techniques.

[35]  Jay R Lieberman,et al.  Osteoinductivity of commercially available demineralized bone matrix. Preparations in a spine fusion model. , 2004, The Journal of bone and joint surgery. American volume.

[36]  T. Albert,et al.  A Pilot Study Evaluating the Safety and Efficacy of OP-1 Putty (rhBMP-7) as a Replacement for Iliac Crest Autograft in Posterolateral Lumbar Arthrodesis for Degenerative Spondylolisthesis , 2004, Spine.

[37]  C. Branch,et al.  Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. , 2004, The spine journal : official journal of the North American Spine Society.

[38]  W. Walsh,et al.  Spinal fusion using an autologous growth factor gel and a porous resorbable ceramic , 2004, European Spine Journal.

[39]  B. Weiner,et al.  Efficacy of Autologous Growth Factors in Lumbar Intertransverse Fusions , 2003, Spine.

[40]  T. Kai,et al.  In Vivo Evaluation of Bone Marrow Stromal-Derived Osteoblasts-Porous Calcium Phosphate Ceramic Composites as Bone Graft Substitute for Lumbar Intervertebral Spinal Fusion , 2003, Spine.

[41]  T. Albert,et al.  Donor Site Morbidity After Anterior Iliac Crest Bone Harvest for Single-Level Anterior Cervical Discectomy and Fusion , 2003, Spine.

[42]  S. Boden,et al.  Use of Recombinant Human Bone Morphogenetic Protein-2 to Achieve Posterolateral Lumbar Spine Fusion in Humans: A Prospective, Randomized Clinical Pilot Trial 2002 Volvo Award in Clinical Studies , 2002, Spine.

[43]  R. Balderston,et al.  Clinical and Radiographic Outcomes of Anterior Lumbar Interbody Fusion Using Recombinant Human Bone Morphogenetic Protein-2 , 2002, Spine.

[44]  C. Dickman,et al.  Anterior Lumbar Interbody Fusion Using rhBMP-2 With Tapered Interbody Cages , 2002, Journal of spinal disorders & techniques.

[45]  R. Holmes,et al.  Hydroxyapatite/Calcium Carbonate (HA/CC) vs. Plaster of Paris: A Histomorphometric and Radiographic Study in a Rabbit Tibial Defect Model , 2002, Calcified Tissue International.

[46]  P. Holtom,et al.  Comparison of Anterior and Posterior Iliac Crest Bone Grafts in Terms of Harvest-Site Morbidity and Functional Outcomes , 2002, The Journal of bone and joint surgery. American volume.

[47]  W. Hutton,et al.  Delivery of Recombinant Human Bone Morphogenetic Protein-2 Using a Compression-Resistant Matrix in Posterolateral Spine Fusion in the Rabbit and in the Non-Human Primate , 2002, Spine.

[48]  P. Aspenberg,et al.  Platelet concentrate increases bone ingrowth into porous hydroxyapatite. , 2002, Orthopedics.

[49]  S. Boden Evaluation of carriers of bone morphogenetic protein for spinal fusion. , 2001, Spine.

[50]  M. Salamon,et al.  The Role of Human Bone Morphogenetic Proteins in Spinal Fusion , 2000, The Journal of the American Academy of Orthopaedic Surgeons.

[51]  S. Boden,et al.  Posterolateral Lumbar Intertransverse Process Spine Arthrodesis With Recombinant Human Bone Morphogenetic Protein 2/Hydroxyapatite‐Tricalcium Phosphate After Laminectomy in the Nonhuman Primate , 1999, Spine.

[52]  M. Marone,et al.  Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. , 1999, Journal of spinal disorders.

[53]  Paramore Cg The safety of OP-1 for lumbar fusion with decompression-- a canine study. , 1999 .

[54]  J. Wozney,et al.  Safety of Recombinant Human Bone Morphogenetic Protein‐2 After Spinal Laminectomy in the Dog , 1999, Spine.

[55]  L. Titus,et al.  New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. , 1999, Spine.

[56]  W. Hutton,et al.  The use of coralline hydroxyapatite with bone marrow, autogenous bone graft, or osteoinductive bone protein extract for posterolateral lumbar spine fusion. , 1999, Spine.

[57]  J. Lotz,et al.  Use of a Collagen‐Hydroxyapatite Matrix in Spinal Fusion: A Rabbit Model , 1998, Spine.

[58]  V. Traynelis,et al.  A comparative analysis of fusion rates and donor-site morbidity for autogeneic rib and iliac crest bone grafts in posterior cervical fusions. , 1998, Journal of neurosurgery.

[59]  M. Mackay,et al.  1997 Volvo Award Winner in Clinical Studies: Degenerative Lumbar Spondylolisthesis With Spinal Stenosis: A Prospective, Randomized Study Comparing Decompressive Laminectomy and Arthrodesis With and Without Spinal Instrumentation , 1997, Spine.

[60]  S. Eiskjær,et al.  1997 Volvo Award Winner in Clinical Studies: The Effect of Pedicle Screw Instrumentation on Functional Outcome and Fusion Rates in Posterolateral Lumbar Spinal Fusion: A Prospective, Randomized Clinical Study , 1997, Spine.

[61]  J. Goulet,et al.  Autogenous Iliac Crest Bone Graft: Complications and Functional Assessment , 1997, Clinical orthopaedics and related research.

[62]  R. Delamarter,et al.  Effective Doses of Recombinant Human Bone Morphogenetic Protein‐2 in Experimental Spinal Fusion , 1996, Spine.

[63]  Takashi Nakamura,et al.  Establishment of bone morphogenetic protein 2 responsive chondrogenic cell line , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[64]  W. Hutton,et al.  Experimental Spinal Fusion With Recombinant Human Bone Morphogenetic Protein‐2 , 1995, Spine.

[65]  Marc A. Asher,et al.  Iliac Crest Bone Graft Harvest Donor Site Morbidity: A Statistical Evaluation , 1995, Spine.

[66]  Banwart Jc,et al.  Iliac crest bone graft harvest donor site morbidity. A statistical evaluation. , 1995 .

[67]  T. Zdeblick A prospective, randomized study of lumbar fusion. Preliminary results. , 1993, Spine.

[68]  A. Levine,et al.  Chronic Donor Site Pain Complicating Bone Graft Harvesting From the Posterior Iliac Crest for Spinal Fusion , 1992, Spine.

[69]  H N Herkowitz,et al.  Degenerative lumbar spondylolisthesis with spinal stenosis. A prospective study comparing decompression with decompression and intertransverse process arthrodesis. , 1991, The Journal of bone and joint surgery. American volume.

[70]  V. Rosen,et al.  Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[71]  V. Rosen,et al.  Growth factors influencing bone development , 1990, Journal of Cell Science.

[72]  B. Summers,et al.  Donor site pain from the ilium. A complication of lumbar spine fusion. , 1989, The Journal of bone and joint surgery. British volume.

[73]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988, Science.

[74]  M. Urist,et al.  Bone: Formation by Autoinduction , 1965, Science.

[75]  T. Damron Use of 3D beta-tricalcium phosphate (Vitoss) scaffolds in repairing bone defects. , 2007, Nanomedicine.

[76]  John R. Johnson,et al.  Posterolateral lumbar spine fusion with INFUSE bone graft. , 2007, The spine journal : official journal of the North American Spine Society.

[77]  J. Szatkowski,et al.  Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). , 2003, The Journal of bone and joint surgery. American volume.

[78]  B. Cunningham,et al.  Osseointegration of autograft versus osteogenic protein-1 in posterolateral spinal arthrodesis: emphasis on the comparative mechanisms of bone induction. , 2002, The spine journal : official journal of the North American Spine Society.

[79]  M. Hadley,et al.  The safety of OP-1 for lumbar fusion with decompression-- a canine study. , 1999, Neurosurgery.

[80]  V. Rosen,et al.  Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. , 1998, Clinical orthopaedics and related research.

[81]  V. Rosen,et al.  Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. , 1996, Growth factors.

[82]  D. Kingsley,et al.  The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. , 1994, Genes & development.

[83]  M. Chapman,et al.  Morbidity at bone graft donor sites. , 1989, Journal of orthopaedic trauma.

[84]  喜田みどり 悪性グリオーマに対する放射線治療 : 照射野因子に関する prospective randomized clinical study , 1989 .